27 12 Endocrine-Related J-P Bayley and P Devilee PPGL cell lines and xenografts 27:12 R433–R450 Cancer REVIEW Advances in paraganglioma– pheochromocytoma cell lines and xenografts Jean-Pierre Bayley 1 and Peter Devilee 1,2 1Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands 2Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands Correspondence should be addressed to J-P Bayley:
[email protected] Abstract This review describes human and rodent-derived cell lines and xenografts developed over Key Words the last five decades that are suitable or potentially suitable models for paraganglioma– f paraganglioma pheochromocytoma research. We outline the strengths and weaknesses of various f pheochromocytoma models and emphasize the recurring theme that, despite the major challenges f succinate dehydrogenase involved, more effort is required in the search for valid human and animal cell models f models of paraganglioma–pheochromocytoma, particularly those relevant to cancers carrying f cell lines a mutation in one of the succinate dehydrogenase genes. Despite many setbacks, the f xenografts recent development of a potentially important new model, the RS0 cell line, gives reason f SV40 for optimism regarding the future of models in the paraganglioma–pheochromocytoma f MPC field. We also note that classic approaches to cell line derivation such as SV40-mediated f MTT immortalization and newer approaches such as organoid culture or iPSCs have been f imCC insufficiently explored. As many existing cell lines have been poorly characterized, we f hPheo1 provide recommendations for reporting of paraganglioma and pheochromocytoma f PC12 cell lines, including the strong recommendation that cell lines are made widely available via the ATCC or a similar cell repository.